logo
  

Severn Trent Fiscal Year Pretax Profit Rises, Group Turnover Down 0.8%

Severn Trent plc (SVT.L) reported profit before tax of 322.3 million pounds for the year to 31 March 2016 compared to 148.2 million pounds, previous year. Profit to owners of the company increased to 330.0 million pounds from 119.1 million pounds. Earnings per share from continuing operations was 139.4 pence compared to 48.1 pence.

Underlying group pretax profit increased to 313.6 million pounds from 300.4 million pounds, a year ago. Underlying earnings per share was 108.2 pence compared to 106.7 pence.

Turnover decreased year-over-year to 1.79 billion pounds from 1.80 billion pounds. Group turnover was down 0.8% year-on-year due to regulated price decrease.

The board of Severn Trent plc has proposed a final ordinary dividend of 48.40 pence. This gives a total ordinary dividend for the year of 80.66 pence.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
French drug major Sanofi reported Thursday weak profit in its first quarter, despite higher net sales. The company also maintained its fiscal 2024 outlook. Sanofi shares were gaining around 4 percent in Paris trading as well as in pre-market activity on the Nasdaq. While reporting financial results for the first quarter on Wednesday, medical devices company Boston Scientific Corp. (BSX) raised its adjusted earnings and net sales growth guidance for the full-year 2024. For fiscal 2024, the company now projects earnings in a range of $1.43 to $1.48 per share and... Shares of Roche Holding AG were losing around 3 percent in Switzerland after the drug major reported weak sales in its first quarter and confirmed fiscal 2024 outlook. Excluding COVID-19-related products, quarterly sales increasedy 7 percent. For fiscal 2024, Roche continues to expect an increase in group sales in the mid single digit range at constant exchange rates.

This week, we feature Nigeria’s combat with meningitis, Hostile takeover bid for Vanda Pharma, US opioid crisis, Sammy’s Milk’s safety concerns, and X4’s Mavorixafor’s fast-track status.

View More Videos
RELATED NEWS
Follow RTT